Oncternal Therapeutics : R&D Day, January 25, 2022

Oncternal

R&D Day

Hematological

Malignancies and

Prostate Cancer

J a n 2 5 , 2 0 2 2

N e w S c i e n c e . N e w C a n c e r T h e r a p i e s . N e w H o p e .

Oncternal R&D Day - January 25, 2022

1

Agenda

		Topics	Presented by
		Introduction	• Jim Breitmeyer, MD, PhD CEO Oncternal Therapeutics
		Heme Malignancies
		• Lymphoma / MCL treatment overview	• Michael Wang, MD (MD Anderson Cancer Center)
		• Oncternal Zilovertamab and ROR1 cell therapy	• Oncternal Therapeutics Management
		program update
		• Q&A
		Prostate Cancer
		• Unmet needs in prostate cancer treatment	• Evan Yu, MD (Fred Hutchinson Cancer Research Center)
		• Oncternal ONCT-534Dual-Action AR Inhibitor	• Oncternal Therapeutics Management
		value proposition and other opportunities
		• Q&A
		Wrap-up	• Jim Breitmeyer, MD, PhD CEO Oncternal Therapeutics
Oncternal R&D Day - January 25, 2022	2

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements (including within the meaning of §21E of the U.S. Securities Exchange Act of 1934, as amended, and § 27A of the U.S. Securities Act of 1933, as amended). Forward-looking statements, which generally include statements regarding goals, plans, intentions and expectations, are based upon current beliefs and assumptions of Oncternal Therapeutics, Inc. ("Oncternal") and are not guarantees of future performance. Statements that are not historical facts are forward-looking statements, and include statements regarding the expected timing for achieving key milestones, including the expected initiation of, and elements constituting, the ZILO-301 and ZILO-302 studies, the potential that the ZILO-301 study can serve as a registrational study, the potential enrollment timeline for zilovertamab prostate cancer studies, submission of an Investigational New Drug application for ONCT-808 and completing and announcing results of clinical trials of Oncternal's other product candidates, the anticipated market potential, duration of patent coverage, ability to obtain and maintain favorable regulatory designations, and potential accelerated approval pathways for Oncternal's product candidates and preclinical programs, Oncternal's estimated cash and cash equivalents as of December 31, 2021 and Oncternal's anticipated cash runway.

All forward-looking statements are subject to risks and uncertainties, including risks and uncertainties inherent in Oncternal's business, including risks associated with the clinical development and process for obtaining regulatory approval of Oncternal's product candidates such as potential delays in the commencement, enrollment and completion of clinical trials; the risk that results seen in a case study of one patient likely will not predict the results seen in other patients in the clinical trial; the risk that interim results of a clinical trial do not predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues, and as more patient data become available; potential changes in estimated cash and cash equivalents based on the completion of financial closing procedures and release of complete fourth quarter 2021 results; and other risks described in Oncternal's filings with the U.S. Securities and Exchange Commission ("SEC"). Except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement. All forward-looking statements in this presentation are current only as of the date on which the statements were made. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in Oncternal's filings with the SEC.

Zilovertamab, ONCT-216,ONCT-808, and ONCT-534 are investigational product candidates or preclinical programs that have not been approved by the U.S. Food and Drug Administration for any indication.

This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Oncternal has not independently verified such information and there can be no assurance as to its accuracy.

Oncternal R&D Day - January 25, 2022

3

Clinical stage biotech focused on hematological malignancies and prostate cancer with multiple modalities and deep ROR1 expertise

Hematological Malignancies

Zilovertamab - ROR1 monoclonal antibody

• Demonstrated clinical benefit of combination with ibrutinib in Phase 2 compared to historical ibrutinib monotherapy
• Expect MCL registrational study initiation in 2Q 2022

ONCT-808 - ROR1 CAR-T Cell Therapy

• Expect IND submission in mid 2022

Prostate Cancer

ONCT-534 - Dual Action AR Inhibitor (DAARI)

• First-in-classMOA interacting with both N- terminal Domain and Ligand-Binding Domain of the androgen receptor inducing AR degradation
• Active preclinically against AR amplification, splice variant and LBD mutation models

Zilovertamab - ROR1 monoclonal antibody

• I-INDopen for advanced prostate cancer

ONCT-216- ETS inhibitor - currently under investigation in a Phase 2 study in Ewing sarcoma, preclinical studies in both heme malignancies and prostate cancer underway

Oncternal R&D Day - January 25, 2022

4

Agenda

		Topics	Presented by
		Introduction	• Jim Breitmeyer, MD, PhD CEO Oncternal Therapeutics
		Heme Malignancies
		• Lymphoma / MCL treatment overview	• Michael Wang, MD (MD Anderson Cancer Center)
		• Oncternal Zilovertamab and ROR1 cell therapy	• Oncternal Therapeutics Management
		program update
		• Q&A
		Prostate Cancer
		• Unmet needs in prostate cancer treatment	• Evan Yu, MD (Fred Hutchinson Cancer Research Center)
		• Oncternal ONCT-534Dual-Action AR Inhibitor	• Oncternal Therapeutics Management
		value proposition and other opportunities
		• Q&A
		Wrap-up	• Jim Breitmeyer, MD, PhD CEO Oncternal Therapeutics
Oncternal R&D Day - January 25, 2022	5